---
title: "Topiramate target genetics suggest reduced binge-eating risk via CA4 inhibition"
id: "medrxiv-19-investigating-the-potential-effect-of-topiramate-on-anorexia-nervosa-and-binge"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-investigating-the-potential-effect-of-topiramate-on-anorexia-nervosa-and-binge"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.05.26367397v1?rss=1"
published_at: "2026-11-08T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Topiramate target genetics suggest reduced binge-eating risk via CA4 inhibition
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-investigating-the-potential-effect-of-topiramate-on-anorexia-nervosa-and-binge
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.05.26367397v1?rss=1)
- **Published At:** 2026-11-08T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators applied drug-target **Mendelian randomization** to probe whether pharmacological actions of **topiramate** influence eating-disorder risk. - The team used summary-data-based MR (SMR) with brain- and blood-derived cis-eQTLs for genes encoding topiramate’s molecular targets; five instruments were validated for antiepileptic activity. - Validated genetic instruments included brain expression of **CA4** and CACNB3, and blood expression of CA4, GRIK1, and GRIK3; these mapped to known topiramate targets identified by the authors. - The primary outcomes were anorexia nervosa (AN; 24,223 cases, 1,243,971 controls) and **binge-eating behaviour** (BE; 39,279 cases, 1,227,436 controls); eight additional psychiatric disorders were examined exploratorily. - After correction for multiple testing, genetically predicted inhibition of **CA4** expression in blood associated with reduced BE risk (OR reported in source; p = 0.002), and the signal persisted in SMR-multi (p = 0.0049). - Colocalization analyses offered moderate support for a shared causal variant between CA4 expression and BE (reported PPH4 = 0.58), according to the authors. - No robust evidence linked genetically predicted target perturbation to AN or to the eight exploratory psychiatric outcomes listed by the study team. - Robustness checks performed by the authors included SMR-multi, HEIDI, and colocalization; these were used to assess instrument specificity and shared causal variants. - The study is a preprint and has not been peer reviewed; the authors noted that findings warrant further clinical and functional follow-up rather than immediate clinical application. - The manuscript stated that all data used were publicly available summary statistics and that data produced are contained within the manuscript; no new human-subject data collection was reported.
## Clinical Analysis & Structured Key Points
Investigating the potential effect of topiramate on anorexia nervosa and binge eating behaviour using drug-target Mendelian randomization | medRxiv Skip to main content Investigating the potential effect of topiramate on anorexia nervosa and binge eating behaviour using drug-target Mendelian randomization Kym-Mai Nguyen , Eva Yi-Hsien Chang , Brain Kim , Paul Ebert , Jiayue-Clara Chiang , View ORCID Profile Liang-Dar Hwang doi: https://doi.org/10.64898/2026.11.05.26367397 Kym-Mai Nguyen 1 Institute for Molecular Bioscience, The University of Queensland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eva Yi-Hsien Chang 1 Institute for Molecular Bioscience, The University of Queensland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Brain Kim 2 School of Environment, The University of Queensland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Paul Ebert 2 School of Environment, The University of Queensland Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jiayue-Clara Chiang 1 Institute for Molecular Bioscience, The University of Queensland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Liang-Dar Hwang 1 Institute for Molecular Bioscience, The University of Queensland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Liang-Dar Hwang For correspondence: d.hwang{at}uq.edu.au Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Topiramate is an antiseizure medication used to treat epilepsy and migraine and is commonly prescribed for appetite suppression and weight loss. However, whether its pharmacological actions influence eating disorder risk remains unclear. We applied drug-target Mendelian randomization (MR) to investigate potential causal effects of topiramate on the risk of anorexia nervosa (AN; 24,223 cases and 1,243,971 controls) and binge-eating behaviour (BE; 39,279 cases and 1,227,436 controls) and, exploratorily, eight other psychiatric disorders: attention-deficit/hyperactivity disorder, anxiety disorders, alcohol use disorder, bipolar disorder, major depressive disorder, panic disorder, post-traumatic stress disorder, and schizophrenia. We used summary-data-based Mendelian randomization (SMR) to investigate genetically predicted pharmacological actions of topiramate using brain- and blood-derived cis-expression quantitative trait loci for genes encoding its molecular targets. Five genetic instruments consistent with topiramate's antiepileptic action were validated: CA4 and CACNB3 expression in the brain and CA4, GRIK1, and GRIK3 expression in the blood. Robustness of the findings was assessed using SMR-multi, HEIDI, and colocalization analyses. After multiple-testing correction, genetically predicted inhibition of CA4 expression in blood was associated with decreased BE risk (OR = 0.867, 95% CI = 0.792 - 0.950, p = 0.002) and remained significant in SMR-multi (p = 0.0049). Colocalization provided moderate support for a shared causal variant underlying CA4 expression and BE (PPH4 = 0.58). No robust evidence was identified for AN or the eight exploratory psychiatric outcomes. Overall, our findings warrant further clinical and functional investigations into mechanisms underlying topiramate-associated appetite suppression and weight loss and their relevance to eating-disorder risk. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study only used publicly available summary statistic data. All sources are provided in the manuscript. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 08, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Investigating the potential effect of topiramate on anorexia nervosa and binge eating behaviour using drug-target Mendelian randomization Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Investigating the potential effect of topiramate on anorexia nervosa and binge eating behaviour using drug-target Mendelian randomization Kym-Mai Nguyen , Eva Yi-Hsien Chang , Brain Kim , Paul Ebert , Jiayue-Clara Chiang , Liang-Dar Hwang medRxiv 2026.11.05.26367397; doi: https://doi.org/10.64898/2026.11.05.26367397 Share This Article: Copy Citation Tools Investigating the potential effect of topiramate on anorexia nervosa and binge eating behaviour using drug-target Mendelian randomization Kym-Mai Nguyen , Eva Yi-Hsien Chang , Brain Kim , Paul Ebert , Jiayue-Clara Chiang , Liang-Dar Hwang medRxiv 2026.11.05.26367397; doi: https://doi.org/10.64898/2026.11.05.26367397 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (638) Allergy and Immunology (917) Anesthesia (350) Cardiovascular Medicine (5005) Dentistry and Oral Medicine (496) Dermatology (428) Emergency Medicine (676) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1693) Epidemiology (16265) Forensic Medicine (36) Gastroenterology (1241) Genetic and Genomic Medicine (7279) Geriatric Medicine (751) Health Economics (1093) Health Informatics (5289) Health Policy (1467) Health Systems and Quality Improvement (1832) Hematology (599) HIV/AIDS (1381) Infectious Diseases (except HIV/AIDS) (16490) Intensive Care and Critical Care Medicine (1203) Medical Education (700) Medical Ethics (156) Nephrology (752) Neurology (7598) Nursing (377) Nutrition (1130) Obstetrics and Gynecology (1296) Occupational and Environmental Health (1040) Oncology (3746) Ophthalmology (1093) Orthopedics (409) Otolaryngology (465) Pain Medicine (501) Palliative Medicine (143) Pathology (721) Pediatrics (1858) Pharmacology and Therapeutics (756) Primary Care Research (786) Psychiatry and Clinical Psychology (6131) Public and Global Health (9992) Radiology and Imaging (2532) Rehabilitation Medicine and Physical Therapy (1519) Respiratory Medicine (1269) Rheumatology (661) Sexual and Reproductive Health (804) Sports Medicine (597) Surgery (803) Toxicology (109) Transplantation (319) Urology (308)
## Related Clinical Research

- [White Matter Microstructure Changes in Functional Motor Disorder: Diffusion MRI Findings](https://medichelpline.com/clinical-feed/medrxiv-11-white-matter-microstructural-alterations-and-symptom-correlates-in-functional.md)
- [Between Neuroaffirmation and Access: Parents’ Experiences of Autism Caregiving in England](https://medichelpline.com/clinical-feed/plos-one-12-between-neuroaffirmation-and-access-parents-experiences-of-autism-caregiving-in.md)
- [Ethical Case Series in Pediatric Endocrinology: Practical Management of Four Clinical Dilemmas](https://medichelpline.com/clinical-feed/pubmed-42657774.md) (DOI: 10.1210/clinem/dgag354)
- [Sleep quality, anxiety, and glycemic control in adults with type 2 diabetes](https://medichelpline.com/clinical-feed/pubmed-43013710.md) (DOI: 10.1371/journal.pone.0361467)
- [Real-world Use and Reported Harms of BPC-157 and TB-500 for Musculoskeletal Injury](https://medichelpline.com/clinical-feed/medrxiv-10-real-world-use-dosing-and-reported-side-effects-of-bpc-157-and-tb-500-for.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.